STAT3 and rheumatoid arthritis: These IC50 values were stronger than those of BHPB (5.91 and 6.41 μg/mL equivalent to 23.26 and 25.23 μM) or comparative compounds (curcumin, 4.01 and 5.21 μg/mL equivalent to 10.89 and 14.14 μM; tofacitinib, 4.12 and 5.53 μg/mL equivalent to 13.18 and 17.70 μM) that are currently used clinically for RA treatment targeting STAT3 activation (Supplementary Table S1).